Showing 1151-1160 of 10487 results for "".
Lasers and EBDs: Considerations for Ethnic Skin
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/lasers-and-ebds-considerations-for-ethnic-skin/20145/Monica Li, MD reviews evidence-based practices for using lasers, energy-based devices and minimally invasive procedures to manage benign dermatoses to treat patients with skin of color. She discusses the importance of engaging patients in appropriate pre- and post-treatment care to reduce potentialDermWireTV: AbbVie's Science of Skin Panel, Monkeypox Warning, Recommendations on Skin Cancer Detection Devices, UV Filters and Aquatic Life
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-abbvies-science-of-skin-panel-monkeypox-warning-recommendations-on-skin-cancer-detection-devices-uv-filters-and-aquatic-life/20131/“The Science of Skin: United Beyond the Surface” program sponsored by AbbVie brings together leading dermatologists and patients or caregivers of patients with dermatologic disease to explore the burden of skin diseases on diverse populations and the need for optimized treatment approaches. Seemal DThe Skin Science Podcast: Episode 1 - "The Skin Microbiome" with Doris Day, MD, FAAD, MA
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-skin-science-podcast-episode-1-the-skin-microbiome-with-doris-day-md-faad-ma/20067/Hosted by Thomas Hitchcock, Ph.D., Chief Science Officer at Crown Laboratories, The Skin Science Podcast is a monthly podcast that covers topics relating to skin health. The series will dig into hot topics within dermatology and aesthetics and will challenge the audience to think a bit differently aBiosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentThe Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.Journal Club: Combination Therapy With Dupilumab and Upadacitinib
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-combination-therapy-with-dupilumab-and-upadacitinib/32408/Neal Bhatia, MD, FAAD, and Ted Lain, MD, MBA, FAAD, discuss the International Journal of Dermatology article “Combination Therapy With Upadacitinib and Dupilumab for Severe Atopic Dermatitis,” and their own experiences with similar treatment strategies.Vitiligo Uncovered: Exploring the Latest Advances in Treatment and Care
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/vitiligo-uncovered-exploring-latest-advances-treatment-and-care/29519/In this on-demand webinar, Dr. Domingues and Dr. Silverberg provide a comprehensive overview of vitiligo. This session covers the various types of vitiligo, essential patient evaluation techniques, and understanding disease progression. Learn about treatment strategies from both private practice andDermwireTV: Counterfeit Botox Cases Widen; New HS Treatment Approved in Europe
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-counterfeit-botox-cases-widen-new-hs-treatment-approved-europe/24419/In this episode of DermwireTV, the use of counterfeit Botox continues to widen; a first-of-its-kind drug is approved in Europe for hidradenitis suppurativa; and the PA Perspective series provides tips for training and onboarding in a new practice.Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.A Matter of Scales
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/a-matter-of-scales/19917/The "classic" descriptions of skin diseases and the scales used to assess disease severity often are based on white skin. But skin diseases can appear differently across skin types. The panelists discuss the need for updated tools, including the need to rethink skin type scales.